PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Authors
Keywords
-
Journal
Molecular Cancer
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-08-18
DOI
10.1186/s12943-023-01827-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
- (2023) Fabio Raith et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
- (2023) Ling-Yu Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
- (2023) Elisabetta Tortorella et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
- (2023) Marianna Sirico et al. Cancers
- Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
- (2023) Fabiola Cecchi et al. Cancers
- PI3K–AKT-Targeting Breast Cancer Treatments: Natural Products and Synthetic Compounds
- (2023) Yeqin Yuan et al. Biomolecules
- Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma
- (2023) SHOJI TAKAGI et al. ANTICANCER RESEARCH
- Development and safety of PI3K inhibitors in cancer
- (2023) Miaomiao Yu et al. ARCHIVES OF TOXICOLOGY
- New insights about the PDGF/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies
- (2023) Pratibha Pandey et al. BIOMEDICINE & PHARMACOTHERAPY
- The emerging role of PI3K inhibitors for solid tumour treatment and beyond
- (2023) Carmen Belli et al. BRITISH JOURNAL OF CANCER
- The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer
- (2023) Wei Jiang et al. CANCER LETTERS
- KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics
- (2023) Ioannis A. Voutsadakis CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Long Non-Coding RNAs, Cell Cycle, and Human Breast Cancer
- (2023) Qinan Yin et al. HUMAN GENE THERAPY
- PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
- (2023) Silviu Constantin Badoiu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma
- (2023) Ismael Riquelme et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Curcumin and Plumbagin Synergistically Target the PI3K/Akt/mTOR Pathway: A Prospective Role in Cancer Treatment
- (2023) Iftikhar Ahmad et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Interim results from a phase I/II study of duvelisib PI3Kδγ inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy.
- (2023) Jingxiao Jin et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer
- (2023) Sameh Daher et al. LUNG CANCER
- PI3Kβ controls immune evasion in PTEN-deficient breast tumours
- (2023) Johann S. Bergholz et al. NATURE
- Capivasertib delays disease progression
- (2023) Peter Sidaway Nature Reviews Clinical Oncology
- Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
- (2023) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
- (2023) Delong Meng et al. ONCOGENE
- Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers
- (2023) Lauren M. Brown et al. ONCOGENE
- Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome
- (2023) T. Vidotto et al. Scientific Reports
- Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
- (2023) Alexandre Bertucci et al. Cancers
- Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment
- (2023) Maxim Sidorov et al. Cells
- Mechanisms of human DNA methylation, alteration of methylation patterns in physiological processes and oncology
- (2023) A. Sergeeva et al. GENE
- Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation
- (2023) Bianca Lara Venâncio de Godoy et al. LIFE SCIENCES
- PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
- (2022) Christopher Ronald Funk et al. BLOOD
- LTK fusions: A new target emerges in non-small cell lung cancer
- (2022) Alissa J. Cooper et al. CANCER CELL
- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
- (2022) Felipe Batalini et al. CLINICAL CANCER RESEARCH
- Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001)
- (2022) Sarah K. Tasian et al. HAEMATOLOGICA
- Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review
- (2022) Hajar Alammar et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
- (2022) Senthil Damodaran et al. JOURNAL OF CLINICAL ONCOLOGY
- MiR-421 promotes lipid metabolism by targeting PTEN via activating PI3K/AKT/mTOR pathway in non-small cell lung cancer
- (2022) Yong-Jie Xu et al. Epigenomics
- mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
- (2022) Sahar Mafi et al. Frontiers in Immunology
- Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
- (2022) Sophia Stock et al. Biomedicines
- A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
- (2022) David Qualls et al. Blood Advances
- Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
- (2022) Eugen Tausch et al. BLOOD
- A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
- (2022) Maria A. Pantaleo et al. BMC CANCER
- Resistance to PI3κδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
- (2022) Alberto J. Arribas et al. HAEMATOLOGICA
- At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy
- (2022) Neil Vasan et al. Nature Reviews Clinical Oncology
- Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma
- (2022) Tomi Jun et al. ONCOLOGIST
- Genetics and Epigenetics of Parathyroid Carcinoma
- (2022) Francesca Marini et al. Frontiers in Endocrinology
- PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival
- (2022) Daniela Cochicho et al. Cancers
- PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
- (2022) Yan Peng et al. Frontiers in Oncology
- The bi-steric mTORC1-selective inhibitor RMC-5552 in tumors with activation of mTOR signaling: Preclinical activity in combination with RAS(ON) inhibitors in RAS-addicted tumors, and initial clinical findings from a single agent phase 1/1b study.
- (2022) Howard A. Burris III et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
- (2022) Peter Savas et al. Cancer Discovery
- PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
- (2022) Kunrui Zhu et al. Cells
- Overview of Research into mTOR Inhibitors
- (2022) Beibei Mao et al. MOLECULES
- Akt isoforms in the immune system
- (2022) Mireia Guerau-de-Arellano et al. Frontiers in Immunology
- A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
- (2022) Geoffrey Shouse et al. BLOOD
- Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients
- (2022) Saurabh Yadav et al. BLOOD
- PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients
- (2022) Jun Yao et al. CLINICAL GENETICS
- The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
- (2022) Peace Mabeta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
- (2022) G. Leslie Burnett et al. Journal of Medicinal Chemistry
- Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis
- (2021) Loretah Chibaya et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll)
- (2021) Ishwarya Murali et al. BLOOD
- Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer
- (2021) Priyanka Sharma et al. CLINICAL CANCER RESEARCH
- Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
- (2021) Nathan H. Fowler et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis
- (2021) Radha Mukherjee et al. MOLECULAR CELL
- A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies
- (2021) Neel D. Trivedi et al. Cancer Medicine
- Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)
- (2021) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
- (2021) Komal Jhaveri et al. CLINICAL CANCER RESEARCH
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
- (2021) Chi Yan et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related Therapeutic Perspectives in Esophageal Carcinoma
- (2021) Giovanni Zarrilli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Matthew J Matasar et al. LANCET ONCOLOGY
- Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR +, HER2 –, PIK3CA ‐Mutated Breast Cancer
- (2021) Stuart Turner et al. ONCOLOGIST
- Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
- (2021) Cécile Tomowiak et al. Blood Advances
- A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)
- (2021) Toby A. Eyre et al. BRITISH JOURNAL OF HAEMATOLOGY
- Idelalisib in relapsed/refractory diffuse large B‐cell lymphoma: results from a Nordic Lymphoma Group phase II trial
- (2021) Karin Fjordén et al. BRITISH JOURNAL OF HAEMATOLOGY
- Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
- (2021) Matthew J. Matasar et al. Clinical Lymphoma Myeloma & Leukemia
- GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
- (2021) Camilla Pecoraro et al. DRUG RESISTANCE UPDATES
- Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
- (2021) Giuseppe Curigliano et al. EUROPEAN JOURNAL OF CANCER
- Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
- (2021) Ajay Major et al. HAEMATOLOGICA
- Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial
- (2021) Francisco Bautista et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of duvelisib, a phosphoinositide 3 kinase (PI3K) δ and γ inhibitor, in Chinese patients (pts) with relapsed/refractory follicular lymphoma (R/R FL): A single-arm, open-label, multicenter, phase Ⅱ clinical trial.
- (2021) Zhong Zheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth
- (2021) Bianca J. Lee et al. Nature Chemical Biology
- PI3K inhibitors are finally coming of age
- (2021) Bart Vanhaesebroeck et al. NATURE REVIEWS DRUG DISCOVERY
- Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
- (2021) Le Yu et al. SEMINARS IN CANCER BIOLOGY
- Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
- (2021) Carla L. Alves et al. Nature Communications
- Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
- (2021) Sanjay Chandrasekaran et al. Frontiers in Immunology
- Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
- (2021) Ying Fan et al. JAMA Oncology
- Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
- (2021) Sho Isoyama et al. Journal for ImmunoTherapy of Cancer
- Akt Isoforms: A Family Affair in Breast Cancer
- (2021) Alakananda Basu et al. Cancers
- Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)
- (2021) Rosa Wijnen et al. Cancers
- Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia
- (2021) Bianca J. Lee et al. Frontiers in Oncology
- Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function
- (2021) Honyin Chiu et al. iScience
- The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial
- (2021) Julio C. Chavez et al. BLOOD
- The Expanding Constellation of Histone Post-Translational Modifications in the Epigenetic Landscape
- (2021) Vincenzo Cavalieri Genes
- PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients
- (2021) Chiara Tarantelli et al. Cancers
- DNA Methylation of PI3K/AKT Pathway-Related Genes Predicts Outcome in Patients with Pancreatic Cancer: A Comprehensive Bioinformatics-Based Study
- (2021) Inês Faleiro et al. Cancers
- Targeting Phosphatases and Kinases: How to Checkmate Cancer
- (2021) Alice Turdo et al. Frontiers in Cell and Developmental Biology
- A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
- (2020) N. Nora Bennani et al. BLOOD
- Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
- (2020) Matthew S. Davids et al. CLINICAL CANCER RESEARCH
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
- (2020) Robert H Jones et al. LANCET ONCOLOGY
- Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
- (2020) Georg Lenz et al. LEUKEMIA
- BCAP Regulates Dendritic Cell Maturation Through the Dual-Regulation of NF-κB and PI3K/AKT Signaling During Infection
- (2020) Yuhui Miao et al. Frontiers in Immunology
- Signaling Network of Forkhead Family of Transcription Factors (FOXO) in Dietary Restriction
- (2020) Yizhou Jiang et al. Cells
- Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
- (2020) Alexey V. Danilov et al. CLINICAL CANCER RESEARCH
- Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8 + T cells
- (2020) Connor J. Dwyer et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
- (2020) Cameron Herberts et al. EUROPEAN UROLOGY
- Safety results from phase I/II study of the PI3Kβ inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.
- (2020) Hussein Abdul-Hassan Tawbi et al. JOURNAL OF CLINICAL ONCOLOGY
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
- (2020) Ningni Jiang et al. MOLECULAR BIOLOGY REPORTS
- Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
- (2020) Ramesh K. Ramanathan et al. Targeted Oncology
- BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer
- (2020) Mai Ahmed Shafei et al. Oncotarget
- Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
- (2020) Fei Xu et al. Cell and Bioscience
- Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
- (2020) Thomas J. Kaley et al. Annals of Clinical and Translational Neurology
- Tissue-Specific Metabolic Regulation of FOXO-Binding Protein: FOXO Does Not Act Alone
- (2020) Noriko Kodani et al. Cells
- Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
- (2020) Przemysław Duda et al. Cells
- Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma
- (2020) Koji Izutsu et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
- (2020) Milad Ashrafizadeh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis
- (2020) Qinglin Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?
- (2020) Nicola Fusco et al. Genes
- MicroRNAs: From Mechanism to Organism
- (2020) Philipp J. Dexheimer et al. Frontiers in Cell and Developmental Biology
- PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
- (2020) Catherine L. Tan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
- (2020) Matthew S. Davids et al. LEUKEMIA
- Comprehensive ceRNA network analysis and experimental studies identify an IGF2-AS/miR-150/IGF2 regulatory axis in colorectal cancer
- (2020) Bingxin Liu et al. PATHOLOGY RESEARCH AND PRACTICE
- PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
- (2020) Rui Liu et al. Cell Death & Disease
- Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
- (2020) H.-Y. Yhim et al. ANNALS OF ONCOLOGY
- Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers
- (2020) Elaine S. Tan et al. CANCER
- Immunometabolic Interplay in the Tumor Microenvironment
- (2020) Irem Kaymak et al. CANCER CELL
- PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond
- (2020) Sadegh Fattahi et al. LIFE SCIENCES
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade
- (2019) Jong Lee et al. Cancers
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
- (2019) Panagiotis A Konstantinopoulos et al. LANCET ONCOLOGY
- The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function
- (2019) Stalin Chellappa et al. JOURNAL OF IMMUNOLOGY
- Akt-1 and Akt-2 Differentially Regulate the Development of Experimental Autoimmune Encephalomyelitis by Controlling Proliferation of Thymus-Derived Regulatory T Cells
- (2019) Song Ouyang et al. JOURNAL OF IMMUNOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Conditioned media from adipocytes promote proliferation, migration, and invasion in melanoma and colorectal cancer cells
- (2019) Jeong-Hyeon Ko et al. JOURNAL OF CELLULAR PHYSIOLOGY
- mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
- (2019) Tian Tian et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
- (2019) Sophia Stock et al. INTERNATIONAL JOURNAL OF CANCER
- A patent update on PDK1 inhibitors (2015-present)
- (2019) Simona Sestito et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
- (2019) Zhiyong Wang et al. CANCER RESEARCH
- ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer
- (2019) Qisang Guo et al. GENE
- Brassinin Represses Invasive Potential of Lung Carcinoma Cells through Deactivation of PI3K/Akt/mTOR Signaling Cascade
- (2019) Min Hee Yang et al. MOLECULES
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression
- (2019) Junli Deng et al. BMC CANCER
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model
- (2019) Chulwon Kim et al. Biomolecules
- PIK3CA mutation and clinicopathological features of colorectal cancer: a systematic review and Meta-Analysis
- (2019) Juan Jin et al. ACTA ONCOLOGICA
- Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group
- (2019) Leo Mascarenhas et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- Overview of the relevance of PI3K pathway in HR-positive breast cancer
- (2019) N Vasan et al. ANNALS OF ONCOLOGY
- Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
- (2019) Pamela T. Soliman et al. CLINICAL CANCER RESEARCH
- PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
- (2019) Petra Hillmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Phase Ib Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity-Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma
- (2019) Lara A. Dunn et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer
- (2019) Tugba Kizilboga et al. BMC CANCER
- Farnesol abrogates epithelial to mesenchymal transition process through regulating Akt/mTOR pathway
- (2019) Jong Hyun Lee et al. PHARMACOLOGICAL RESEARCH
- Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy
- (2019) Devesh Tewari et al. SEMINARS IN CANCER BIOLOGY
- Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study
- (2018) David K. Lau et al. BRITISH JOURNAL OF CANCER
- Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
- (2018) R D Kim et al. BRITISH JOURNAL OF CANCER
- Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance
- (2018) Justin Kale et al. EMBO REPORTS
- GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
- (2018) Maolan Li et al. GUT
- DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions
- (2018) Ayodele Gomih et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
- (2018) Hans Tesch et al. INTERNATIONAL JOURNAL OF CANCER
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
- (2018) Suzanne Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy
- (2018) Nahal Haddadi et al. Molecular Cancer
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer
- (2018) Myung Woul Han et al. ORAL ONCOLOGY
- How to explain the AKT phosphorylation of downstream targets in the wake of recent findings
- (2018) Anil K. Agarwal PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
- (2018) Jake S. O’Donnell et al. SEMINARS IN CANCER BIOLOGY
- Prostate Power Play: Does Pik3ca Accelerate Pten -Deficient Cancer Progression?
- (2018) Joanna Triscott et al. Cancer Discovery
- Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth
- (2018) Helen B. Pearson et al. Cancer Discovery
- Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
- (2018) Guy Jerusalem et al. JAMA Oncology
- Understanding the biology of HER3 receptor as a therapeutic target in human cancer
- (2018) Hui Lyu et al. Acta Pharmaceutica Sinica B
- Critical role of FOXO3a in carcinogenesis
- (2018) Ying Liu et al. Molecular Cancer
- CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia
- (2018) Yun-Jung Chiang et al. ONCOGENE
- HGF-mediated crosstalk between cancer-associated fibroblasts and MET-unamplified gastric cancer cells activates coordinated tumorigenesis and metastasis
- (2018) Xusheng Ding et al. Cell Death & Disease
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
- (2018) Christopher Groth et al. BRITISH JOURNAL OF CANCER
- A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors
- (2018) Yuichi Ando et al. CANCER SCIENCE
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression
- (2018) Shuai Dong et al. JOURNAL OF CLINICAL INVESTIGATION
- The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer
- (2018) Wei Jiang et al. Journal of Hematology & Oncology
- Long Noncoding RNA IGF2AS is Acting as an Epigenetic Tumor Suppressor in Human Prostate Cancer
- (2018) Qiang Chen et al. UROLOGY
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells
- (2017) Russell G. Jones et al. IMMUNITY
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- AKT Inhibition in Solid Tumors With AKT1 Mutations
- (2017) David M. Hyman et al. JOURNAL OF CLINICAL ONCOLOGY
- Akt Signaling Pathway in Macrophage Activation and M1/M2 Polarization
- (2017) Eleni Vergadi et al. JOURNAL OF IMMUNOLOGY
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- A novel function of hepatocyte growth factor in the activation of checkpoint kinase 1 phosphorylation in colon cancer cells
- (2017) Na Song et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40
- (2017) Haijuan Yang et al. NATURE
- EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
- (2017) Tsukasa Shibue et al. Nature Reviews Clinical Oncology
- Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1
- (2017) Jun Wang et al. Nature Communications
- mTORC2 signalling regulates M2 macrophage differentiation in response to helminth infection and adaptive thermogenesis
- (2017) R. W. Hallowell et al. Nature Communications
- Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality
- (2017) Mayumi Kitagawa et al. Nature Communications
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis
- (2017) King Xin Koh et al. Oncotarget
- Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial
- (2017) Jeffrey A Jones et al. Lancet Haematology
- Targeting PDK1 for Chemosensitization of Cancer Cells
- (2017) Aikaterini Emmanouilidi et al. Cancers
- Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.
- (2017) Pamela N. Munster et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
- (2016) A. Patnaik et al. ANNALS OF ONCOLOGY
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
- (2016) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer
- (2016) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
- (2016) D. J. Kwiatkowski et al. CLINICAL CANCER RESEARCH
- Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
- (2016) Bernard Escudier et al. EUROPEAN JOURNAL OF CANCER
- Asparaginyl endopeptidase promotes proliferation and invasiveness of prostate cancer cells via PI3K/AKT signaling pathway
- (2016) Wenjing Zhu et al. GENE
- Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation
- (2016) Stanley Ching-Cheng Huang et al. IMMUNITY
- G protein-coupled receptors (GPCRs) That Signal via Protein Kinase A (PKA) Cross-talk at Insulin Receptor Substrate 1 (IRS1) to Activate the phosphatidylinositol 3-kinase (PI3K)/AKT Pathway
- (2016) Nathan C. Law et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
- (2016) Iñigo Landa et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma
- (2016) Agnieszka Korfel et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
- (2016) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Phosphatidylinositol 3-Kinase/Akt Mediates Integrin Signaling To Control RNA Polymerase I Transcriptional Activity
- (2016) Chuanyue Wu et al. MOLECULAR AND CELLULAR BIOLOGY
- Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer
- (2016) C. Stottrup et al. MOLECULAR CANCER THERAPEUTICS
- Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity
- (2016) Chong T. Luo et al. NATURE
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management
- (2016) Khurum H. Khan et al. ONCOLOGIST
- Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway
- (2016) Chakrabhavi Dhananjaya Mohan et al. PLoS One
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
- (2016) K. Okkenhaug et al. Cancer Discovery
- Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
- (2016) X. Le et al. Cancer Discovery
- A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-κB regulates head and neck squamous cell carcinoma proliferation
- (2016) Zhipeng Li et al. Oncotarget
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives
- (2016) Pei Shi Ong et al. Frontiers in Pharmacology
- Idelalisib
- (2015) Arpita Shah et al. ANNALS OF PHARMACOTHERAPY
- A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia
- (2015) S. M. O'Brien et al. BLOOD
- Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
- (2015) Carlotta Costa et al. CANCER CELL
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population
- (2015) Neil E. Bhola et al. CANCER RESEARCH
- FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma
- (2015) B. W. Miller et al. CLINICAL CANCER RESEARCH
- mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
- (2015) Kristen N. Pollizzi et al. JOURNAL OF CLINICAL INVESTIGATION
- Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors
- (2015) Timothy J. Hobday et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
- (2015) Brian M. Slomovitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Targeting the translation machinery in cancer
- (2015) Mamatha Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- PTEN and PI3K/AKT in non-small-cell lung cancer
- (2015) Cristina Pérez-Ramírez et al. PHARMACOGENOMICS
- PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
- (2015) Ana Bosch et al. Science Translational Medicine
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers
- (2015) Wen-Liang Fang et al. Oncotarget
- Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+T-cell proliferation and survival
- (2015) Rasha Abu Eid et al. OncoImmunology
- Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
- (2015) Nicole M. Davis et al. Oncotarget
- γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model
- (2015) Kodappully Sivaraman Siveen et al. Oncotarget
- PI3K/AKT signaling pathway and cancer: an updated review
- (2014) Miriam Martini et al. ANNALS OF MEDICINE
- Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma
- (2014) D. J. Inwards et al. ANNALS OF ONCOLOGY
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- , as therapy for previously treated indolent non-Hodgkin lymphoma
- (2014) I. W. Flinn et al. BLOOD
- A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
- (2014) B. S. Kahl et al. BLOOD
- FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway
- (2014) Aifu Lin et al. CANCER RESEARCH
- Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors
- (2014) D. R. Feldman et al. CLINICAL CANCER RESEARCH
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- (2014) Dejan Juric et al. NATURE
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- Genomic and molecular characterization of esophageal squamous cell carcinoma
- (2014) De-Chen Lin et al. NATURE GENETICS
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer
- (2014) Nikhil Wagle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1
- (2014) Sharmila Mallya et al. PLoS One
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
- (2014) Jennifer A. Perry et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FOXO transcription factors: key regulators of cellular quality control
- (2014) Ashley E. Webb et al. TRENDS IN BIOCHEMICAL SCIENCES
- Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
- (2014) N. Wagle et al. Cancer Discovery
- Posttranslational regulation of Akt in human cancer
- (2014) Chia-Hsin Chan et al. Cell and Bioscience
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine
- (2013) Olafur A. Stefansson et al. AMERICAN JOURNAL OF PATHOLOGY
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- XIAP: inhibitor of two worlds
- (2013) Paola Merlo et al. EMBO JOURNAL
- Targeting Cdc42 in cancer
- (2013) Luis E Arias-Romero et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Kinase AKT controls innate immune cell development and function
- (2013) Yan Zhang et al. IMMUNOLOGY
- Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics
- (2013) Maria D'Agostino et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
- (2013) Ningshu Liu et al. MOLECULAR CANCER THERAPEUTICS
- mTORC1 couples immune signals and metabolic programming to establish Treg-cell function
- (2013) Hu Zeng et al. NATURE
- PI3K in cancer–stroma interactions: bad in seed and ugly in soil
- (2013) E Hirsch et al. ONCOGENE
- The regulatory roles of phosphatases in cancer
- (2013) J Stebbing et al. ONCOGENE
- Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain
- (2013) Ambuj Kumar et al. PLoS One
- PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
- (2013) Minmin Song et al. PLoS One
- PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1
- (2013) H. Ebi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN
- (2013) Shou-mei Yang et al. TOXICOLOGY
- A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
- (2013) H. Shi et al. Cancer Discovery
- Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer
- (2013) L-Y Huw et al. Oncogenesis
- Regulation of Immune Responses by mTOR
- (2012) Jonathan D. Powell et al. Annual Review of Immunology
- Induction of IL-4R -dependent microRNAs identifies PI3K/Akt signaling as essential for IL-4-driven murine macrophage proliferation in vivo
- (2012) D. Ruckerl et al. BLOOD
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies
- (2012) T. Alain et al. CANCER RESEARCH
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ T regulatory cell subpopulations
- (2012) C. Scotta et al. HAEMATOLOGICA
- Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: Clinical and molecular correlates
- (2012) Mark A. Dickson et al. INTERNATIONAL JOURNAL OF CANCER
- The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
- (2012) Bao Hoang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The landscape of cancer genes and mutational processes in breast cancer
- (2012) Philip J. Stephens et al. NATURE
- Novel Foxo1-dependent transcriptional programs control Treg cell function
- (2012) Weiming Ouyang et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
- (2012) C. Parikh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades
- (2012) Seong Won Kim et al. PROSTATE
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Akt, FoxO and regulation of apoptosis
- (2011) Xinbo Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer
- (2011) Akira Ooki et al. BMC CANCER
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- Insulin receptor and cancer
- (2011) A. Belfiore et al. ENDOCRINE-RELATED CANCER
- Mammalian Target of Rapamycin Complex 2 (mTORC2) Negatively Regulates Toll-like Receptor 4-mediated Inflammatory Response via FoxO1
- (2011) Jonathan Brown et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Combining mTor Inhibitors With Rapamycin-resistant T Cells: A Two-pronged Approach to Tumor Elimination
- (2011) Leslie E Huye et al. MOLECULAR THERAPY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors
- (2011) A. Chakrabarty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The mTOR-Regulated Phosphoproteome Reveals a Mechanism of mTORC1-Mediated Inhibition of Growth Factor Signaling
- (2011) P. P. Hsu et al. SCIENCE
- AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer
- (2011) Yuanzi Yu et al. TUMOR BIOLOGY
- mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
- (2011) V. S. Rodrik-Outmezguine et al. Cancer Discovery
- The Adenovirus-Mediated Transfer ofPTENInhibits the Growth of Esophageal Cancer Cellsin Vitroandin Vivo
- (2010) Yong-an ZHOU et al. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
- 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors
- (2010) Qing-Bai She et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- Phosphatase PRL-3 Is a Direct Regulatory Target of TGF in Colon Cancer Metastasis
- (2010) Y. Jiang et al. CANCER RESEARCH
- Regulation of Akt signaling activation by ubiquitination
- (2010) Wei-Lei Yang et al. CELL CYCLE
- Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
- (2010) P. Valent CURRENT CANCER DRUG TARGETS
- Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
- (2010) Andrew J. Wagner et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set
- (2010) E. S. Park et al. MOLECULAR CANCER THERAPEUTICS
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A methylation and phosphorylation switch between an adjacent lysine and serine determines human DNMT1 stability
- (2010) Pierre-Olivier Estève et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
- (2010) V. E. Kwitkowski et al. ONCOLOGIST
- Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
- (2009) Kuan-Ting Kuo et al. AMERICAN JOURNAL OF PATHOLOGY
- Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
- (2009) T. W. Miller et al. CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Inactivation of p53 and Pten promotes invasive bladder cancer
- (2009) A. M. Puzio-Kuter et al. GENES & DEVELOPMENT
- Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
- (2009) Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- mTOR regulates memory CD8 T-cell differentiation
- (2009) Koichi Araki et al. NATURE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- The TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
- (2008) Thomas Weichhart et al. IMMUNITY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice
- (2008) Y. Takei et al. MOLECULAR CANCER THERAPEUTICS
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PTEN–PI3K pathway: of feedbacks and cross-talks
- (2008) A Carracedo et al. ONCOGENE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- FOXOs, cancer and regulation of apoptosis
- (2008) Z Fu et al. ONCOGENE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started